Cardinal Health, Inc. (CAH), headquartered in Dublin, Ohio, operates as a healthcare services and products company. Valued at $54.6 billion by market cap, the company's services include pharmaceutical distribution, health-care product manufacturing, distribution and consulting services, drug delivery systems development, pharmaceutical packaging, automated dispensing systems manufacturing, and retail pharmacy franchising.
Companies worth $10 billion or more are generally described as "large-cap stocks," and CAH perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical distribution industry. As one of the top three U.S. pharma wholesalers, CAH holds a commanding market position. Its diversified pharmaceutical and medical distribution portfolio, broadens its customer base, adds resilience to market swings, and creates multiple revenue streams with cross-selling opportunities.
Billionaire Charlie Munger, Who Died at 99, Skipped Insurance on His Mansion Since He Could Just Write a Check to Rebuild — 'All Intelligent People Do It My Way'
Nvidia CEO Jensen Huang Just Dropped Huge News for This Cybersecurity Stock
How to Play GME Stock as GameStop CEO Ryan Cohen Buys $20.3 Million in Shares

#market #Health #Manufacturing #systems

With a market cap of $138.2 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy.
Companies valued at $10 billion or more are generally classified as "large-cap" stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ***** eX Deal Could Meaningfully Accelerate Growth for Technip Stock

#company #bristol #squibb #Stock

Shell has agreed to take full control of U.S. convenience store operator and fuel distributor Tri Star Energy, in a transaction that will more than double the energy major's company-owned convenience retail footprint in the United States.
Equilon Enterprises, which operates as Shell Oil Products US, will increase its ownership of Nashville-based Tri Star from 33% to 100%. The acquisition includes 320 fuel and convenience retail sites in Tennessee and surrounding states, along with fuel-supply agreements covering another 552 dealer-owned locations. Financial terms were not disclosed.
Shell is acquiring the remaining interest from The Parman Corporation, Kimbro Oil Company and their subsidiaries. The deal is expected to close by the end of 2026, subject to regulatory approval and customary closing conditions.
The transaction represents a substantial expansion of Shell's directly controlled retail operations. While Shell already has around 12,000 branded fuel and convenience sites across 49 U.S. states, the vast majority are operated by wholesalers or dealers rather than owned directly by the company. Shell says its U.S. network serves more than 7 million customers per day.
Following completion, Tri Star will be operated by Texas Petroleum Group, a wholly owned unit of Shell Mobility & Convenience US. Shell expects the combined business to have nearly 550 company-owned convenience retail locations and supply agreements with around 650 dealer-owned sites across the southern United States.
Tri Star, founded in 2000, operates convenience-store brands including Twice Daily, Sudden Service and Little General and also owns the White Bison Coffee brand. Its wholesale fuel operation reaches multiple states, giving Shell additional exposure to both fuel distribution and higher-margin convenience and food-and-beverage sales.

#shell #convenience #retail

On August 14, RLX Technology (NYSE:RLX) reported second-quarter results that told two different stories at once. International sales climbed to roughly 70% of revenue as the company absorbed a new European distribution partner, even as trade normalization back home pulled growth down from where the year started. RLX is no longer just an e-vapor device maker. It is trying to become a diversified, direct-to-retail nicotine platform before its home market tightens further.
Net revenues reached RMB1.01 billion in the second quarter, up 14.8% year over year, powered by international volume growth and the contribution of a company RLX acquired in May 2025. Gross margin expanded to 35.4% from 27.5% a year earlier, a jump management credited to supply chain optimization and a better mix of products and geographies. Non-GAAP income from operations rose 28.8% to RMB149.6 million, marking the 11th straight quarter of positive non-GAAP operating profit.
In July 2026, RLX took a 51% controlling stake in a Western European distributor that reaches 30,000 retail endpoints and runs a digital ordering platform connecting 20,000 independent merchants, a deal management framed as the next step in building direct retail relationships rather than depending on layers of wholesalers. CEO Kate ****** argued that as vaping hardware becomes commoditized, "competition is shifting from pure product development to route-to-market execution."
The company is also leaning into modern oral nicotine pouches as a new growth line and is building a manufacturing hub in Southeast Asia to produce them at scale, all while sitting on RMB13.9 billion in total capital resources as of June 30, 2026.
The same quarter that produced margin expansion also produced warning signs closer to home. Mainland China revenue is now expected to be roughly flat for the full year, and Sam Tsang, the company's head of capital markets, said the "procedural time line for government approval has become more conservative" as domestic enforcement tightens. Revenue and margins both moderated sequentially from the first quarter, which had been inflated by a shipment pull-forward tied to regulatory export changes, and management flagged that the elevated 35.4% margin should settle into a lower range going forward.

#revenue #retail

WASHINGTON, Aug 14 (Reuters) - U.S. business inventories were unchanged in June as an increase in stocks at wholesalers was ‌offset by a decline at retailers, reflecting strong domestic demand ‌in the second quarter.
The flat reading in inventories followed a 0.4% rise in May, the Commerce Department's Census Bureau said on Friday. Economists polled by Reuters had forecast inventories, a key component of gross domestic product and one of the most volatile, edging up 0.1% in June.
Inventories ‌increased 3.0% year-on-year in June.
Business ⁠inventories have been drawn down for five straight quarters amid robust domestic demand, a mix of consumer ⁠spending and business investment tied to artificial intelligence.
They subtracted from gross domestic product growth in the second quarter. The economy grew at a 1.5% annualized rate last quarter, though domestic demand increased at its fastest ‌pace in more than three years.

#domestic #june #demand #quarter

A Chapter 7 bankruptcy generally involves liquidation, but it doesn't necessarily mean the end of the businesses or brands connected to the person or business who filed.
Big Lots, for example, filed for Chapter 7 bankruptcy and was liquidated, but some of its stores and the right to use its name were sold to Variety Wholesalers. That transaction gave Variety Wholesalers the right to reopen between a quarter and half of the chain's roughly 800 stores.
In many cases, however, in a Chapter 7 filing, the brands go away. When it comes to Nick Pihakis, who owns Pihakis Restaurant Group, it's unclear whether any of his company's many restaurants, some of which have already closed, will survive.
The case was filed by Pihakis individually, not by Pihakis Restaurant Group or any affiliated LLCs. Huntsville attorney Kevin Heard of Heard Ary & Dauro is representing Pihakis.
Pihakis has a long list of creditors that has gotten longer since TheStreet last reported on his situation in May.

#wholesalers #heard #brands

A Chapter 7 bankruptcy generally involves liquidation, but it doesn't necessarily mean the end of the businesses or brands connected to the person or business who filed.
Big Lots, for example, filed for Chapter 7 bankruptcy and was liquidated, but some of its stores and the right to use its name were sold to Variety Wholesalers. That transaction gave Variety Wholesalers the right to reopen between a quarter and half of the chain's roughly 800 stores.
In many cases, however, in a Chapter 7 filing, the brands go away. When it comes to Nick Pihakis, who owns Pihakis Restaurant Group, it's unclear whether any of his company's many restaurants, some of which have already closed, will survive.
The case was filed by Pihakis individually, not by Pihakis Restaurant Group or any affiliated LLCs. Huntsville attorney Kevin Heard of Heard Ary & Dauro is representing Pihakis.
Pihakis has a long list of creditors that has gotten longer since TheStreet last reported on his situation in May.

#wholesalers #group

Nike (NKE), the iconic sneaker brand, is having a tough time. The stock closed in the red for the last four consecutive years and is down nearly 32% for this year. NKE stock peaked in November 2021 and has since lost three-fourths of its market cap.
Amid a sagging stock price, Nike brought back Elliott Hill, a company veteran, to lead the company in October 2024. Hill succeeded John Donahoe, whose strategy of focusing on direct sales while cutting down on wholesale sales backfired after the initial success during the Covid-19 pandemic. In hindsight, the company miscalculated the brand pull and lost out to other brands that were well stocked at third-party stores. Along with mending relations with wholesalers, Hill has shifted Nike's attention back towards sports, which used to be its USP. However, these measures haven't helped reverse the slide in NKE stock.
Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!
A sagging stock price coupled with gradual dividend hikes has pushed Nike's dividend yield to nearly 3.8%, which is near the record highs that we saw last month when the stock hit its 52-week lows. In my previous article, I noted that while Nike's risk-reward has improved, it's not a compelling buy yet. Let's explore if the stock can fit into portfolios of investors who crave high dividend stocks, beginning with the company's recent financial performance.
Nike's revenues fell 1% year-over-year (YoY) in its fiscal Q4 2026, which ended in May, even though the metric came in slightly better than feared. Wholesale revenues rose 4% in the quarter but couldn't fully offset the 7% decline in Direct sales. Looking at the geographical breakdown, North America revenues rose 3% while sales in Greater China fell 12% in the quarter.

Private-equity firm Apheon has acquired Alma, the new French food group created by combining Foo Seng and Varachaux.
The deal, struck for an undisclosed sum, comes just months after Asian snacks business Foo Seng and meal-components supplier Varachaux were merged to form Alma.
In a statement today (7 July), Apheon said the deal "marks the beginning of a new phase of growth for Alma", pointing to its "proven playbook for scaling businesses through targeted consolidation" in European markets.
Combined, Alma employs around 115 people and generates around €40m ($45.7m) in revenue.
The company supplies to wholesalers, foodservice operators and retailers, primarily in France.

Choosing between Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) means deciding whether you prefer a pure-play pharmaceutical company trading at a deep discount or a diversified giant with higher growth.
While both operate within the same broader sector, their business models differ significantly. Bristol Myers focuses heavily on drug development for serious diseases, while Johnson & Johnson splits its attention between medicine and medical devices. Let's compare them and weigh their specific risks and financial health.
Bristol Myers operates as a major player in the pharmaceutical stocks **** e, focusing on oncology, hematology, and immunology. The company sells its innovative medicines primarily to wholesalers and specialty pharmacies, relying on established distribution channels for top products like Opdivo and Eliquis. Key commercial alliances with Merck (NYSE:MRK) and BioNTech (NASDAQ:BNTX) help Bristol Myers expand its reach in specialized therapeutic areas.
In fiscal 2025, revenue reached nearly $48.2 billion, reflecting a slight decrease of approximately 0.2% compared to the previous year. The company reported net income of roughly $7.1 billion during this period, resulting in a net margin of approximately 14.6%. This was a significant recovery from the prior fiscal year, when Bristol Myers recorded a substantial net loss following specific business shifts.
As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.6. This figure, which compares total debt to the value of shareholder equity, suggests a higher reliance on borrowed funds. The current ratio, which measures the company's ability to cover short-term debts with current **** ets, is approximately 1.3, while free cash flow reached nearly $12.8 billion.

By Jonathan Stempel
June 15 (Reuters) - The U.S. Supreme Court turned away on Monday a gun industry challenge to a New York law that permits lawsuits against gun makers, wholesalers and dealers for endangering people's safety through sales of firearms and ammunition.
The justices declined to ‌hear an appeal by an industry trade group, the National Shooting Sports Foundation, of a lower court's ruling upholding the law, which New York ‌calls a public nuisance statute. The group had argued that the law unconstitutionally conflicted with federal law.
Gun companies including Smith & Wesson, Ruger, Beretta, Glock, Sig Sauer and Sturm joined the appeal.
The Supreme Court in 2025 spared Smith & Wesson from a lawsuit by Mexico's government accusing the company of aiding illegal gun trafficking to drug cartels.